

DAFTAR PUSTAKA

1. WHO. HIV/AIDS [internet]. c2013 [cited 2013 November 20]. Available from : http://www.who.int/topics/hiv_aids/en/.
2. Lindegren ML, Steinberg S, Robert H. Byers Jr. Epidemiology of HIV/AIDS. Elsevier. 2000; 1-20. (Abstract).
3. UNAIDS. UNAIDS Report On The Global AIDS Epidemic 2012. Geneva (Switzerland); 2012.
4. DEPKES. Pedoman Tata Laksana Infeksi HIV dan Terapi Antiretroviral pada Anak di Indonesia. 2008.
5. Direktorat Jenderal PP dan PL Kementerian Kesehatan RI. Laporan Situasi Perkembangan HIV/AIDS di Indonesia s.d. 30 September 2013. Jakarta (Indonesia); 2013.
6. Nasronudin. Transmisi Infeksi HIV. In: HIV dan AIDS Pendekatan Biologi Molekuler, Klinis, dan Sosial. Editor: Barakbah J, Soewandjojo E, Suharto, Hadi U, Astuti WD. Surabaya: Airlangga University Press; 2007. p. 15.
7. Ratridewi, irene. Evaluasi Jumlah Sel T-CD4 dan Berat Badan Anak dengan HIV/AIDS yang Mendapatkan Anti Retrovirus Lini Pertama di Rumah Sakit Dr. Saiful Anwar Malang. Sari Pediatri. 2009; 11(4)
8. Dina M, Akib AAP, Munasir Z, Kurniawati N. Terapi Antiretroviral Lini Kedua pada HIV Anak di RS. Cipto Mangunkusumo. Sari Pediatri. 2012; 14(2).
9. AIDS MAP. HIV and AIDS Treatment In Practice. Issue 7. 2003.
10. Yasin NM, Maranty H, dan Ningsih WR. Analisis respon terapi antiretroviral pada pasien HIV/AIDS. Majalah Farmasi Indonesia. 2011; 22(3).
11. Olawumi HO, Olatunji PO, Salami AK, Odeigah L, Iseniyi JO. Effect of Highly Active Antiretroviral Therapy on CD4 Count and Weight in AIDS

- Patients Seen at The UITH, Ilorin. *Nig. J. of Clin. Pract.* 2008; 11 (4), 312-15.
12. Song R, Jelagat J, Dzombo D, Mwalimu M, Mandaliya K, Shikely K, dkk. Efficacy of Highly Active Antiretroviral Therapy in HIV-1-Infected Children in Kenya. *J of the american academy of pediatrics.* 2007;120:e856.
 13. Yotebieng M, Van Rie A, Moultrie H, Meyers T. Six-month gain in weight, height, and CD4 predict subsequent antiretroviral treatment responses in HIV-infected South African children. *NIH Public Access-AIDS.* 2010 Jan 2; 24(1):139-46.
 14. WHO. Clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance [internet]. c2005 [cited 2013 November 20]. Available from : <http://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf>:2.
 15. Centers for Disease Control and Prevention [internet]. Atlanta; c2013 [cited 2013 November 20]. Available from : <http://www.cdc.gov/hiv/basics/whatishiv.html>.
 16. UNAIDS. UNAIDS Report On The Global AIDS Epidemic 2013. Geneva (Switzerland); 2013.
 17. AVERT. Asia HIV and AIDS Timeline [internet]. Inggris; c1986-2013 [cited 2013 November 21]. Available from : http://www.avert.org/asia-hiv-aids-timeline.htm#footnote1_n2b5tzb.
 18. Cohen OJ, Fauci AS. Pathogenesis and medical aspects of HIV-1 infection. In: Prof. H. Garna Herry dr.,Sp.A(K), PhD, Buku Ajar Divisi Infeksi dan Penyakit Tropis Departemen Kesehatan Anak Fakultas Kedokteran Universitas Padjadjaran / RSUP DR. Hasan Sadikin Bandung. Jakarta: Sagung Seto; 2012. p.264.
 19. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pencegahan Penularan HIV dari Ibu ke Anak Edisi Kedua. Jakarta; 2012.
 20. Yogev R, Gould CE. Acquired Immunodeficiency Syndrome (human immunodeficiency virus). In: Prof. H. Garna Herry dr.,Sp.A(K), PhD, Buku Ajar Divisi Infeksi dan Penyakit Tropis Departemen Kesehatan

- Anak Fakultas Kedokteran Universitas Padjadjaran / RSUP DR. Hasan Sadikin Bandung. Jakarta: Sagung Seto; 2012. p.286-7.
21. Fowler MG, Roongpisuthipong A. Update on perinatal HIV transmission. *Pediatric Clinic. Pediatric Clinic North America*. 2000; 47(1):21-38. (Abstract)
 22. Sofro MAU, Anurogo D. Wanita HIV Positif Bolehkan Hamil?. In: Desy Wee, editor. *5 Menit Memahami 55 Problematika Kesehatan*. Yogyakarta: D-Medika; 2013. p. 130-55.
 23. Preble EA, Piwoz EG. Prevention of mother to child transmission of HIV in Asia: Practical guidance for programs. USAID. 2001; 169559. (Abstract)
 24. Sufiawati I, Priananto FR. Manifestasi Oral yang Berhubungan dengan Tingkat Imunosupresi pada Anak-Anak yang Terinfeksi HIV/AIDS dan Penatalaksanaannya (Studi Pustaka). *Jurnal Kedokteran Gigi Universitas Padjadjaran*. 2005;17:3-4.
 25. Subowo. *Imunologi Klinik Edisi ke-2*. Jakarta: Sagung Seto; 2013. p. 209.
 26. Mandal BK. Acquired Immunodeficiency Syndrome. In : *Lecture Notes on Infectious Disease - 6th edition*. Editor : Wilkins EGL, Dunbar EM, White RTM. Oxford : Blackwell Publishing Ltd; 2008. p. 169-86.
 27. Nasronudin. Infeksi HIV/AIDS di Indonesia Tahapan Infeksi, Perawatan, Dukungan, dan Prinsip Pengobatan. In: *HIV dan AIDS Pendekatan Biologi Molekuler, Klinis, dan Sosial*. Editor: Barakbah J, Soewandojo E, Suharto, Hadi U, Astuti WD. Surabaya: Airlangga University Press; 2007. p. 266-7.
 28. National Institute of Allergy and Infectious Diseases. Mechanism and Pathogenesis of Pediatric HIV-1 Infection. 1998; PA-98-048.
 29. Nielsen K, McSherry G, Petru A. A descriptive survey of pediatric immunodeficiency virus-infected long-time survivors. *Pediatrics*. 1997;99:e4.

30. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Departemen of Health and Human Service USA. 2013.
31. Arpadi SM, Patricia A. Cuff, Donald P. Kotler, Jack Wang, Marukh Bamji, Michael Lange, et.al. Growth Velocity, Fat-Free Mass and Energy Intake Are Inversely Related to Viral Load in HIV-Infected Children. *The Journal of Nutrition*. 2000; 130: 2498–502.
32. Schwarzwald H, Kline MW. Diagnosis dan clinical manifestation of HIV infection. In: Long SS, Pickering LK, Prober CG, penyunting. *Principles and practice of pediatric infectious disease*. Edisi ke-3. Philadelphia: Churchill Livingstone; 2008. p.654-61.
33. Rivera DM. HIV infection- follow up [internet]. New York; c1994-2013 [cited 2013 November 25]. Available from: <http://emedicine.medscape.com/article/965086-followup>.
34. Sudano, Issabela, Lukas E. Spieker, Georg Noll, Roberto Corti, Rainer Weber, Thomas F. Lüscher. Cardiovascular disease in HIV infection. *Am Heart J*. 2006 Jun; 151(6):1147-55. (Abstract).
35. Herry, Garna. *Buku Ajar Divisi Infeksi dan Penyakit Tropis Departemen Kesehatan Anak Fakultas Kedokteran Universitas Padjadjaran / RSUP DR. Hasan Sadikin Bandung*. Jakarta: Sagung Seto; 2012. p. 305.
36. Wilcox CM, Saag MS. Gastrointestinal Complications of HIV Infection: Changing Priorities in the Haart Era. *Gut*. 2008; 57(6):861-70.
37. Fezoui H, Garnier G, Taillan B, Cassuto JP. Hemostasis anomalies and human immunodeficiency virus infection. *Rev Med Interne*. 1996;17(9):738-45.
38. Bartlett JG. *Penyakit ginjal terkait HIV*. 2009.
39. WHO. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV related disease in adult and children. Geneva (Switzerland); 2007.
40. Colette J. Smith, Caroline A. Sabin, Mike S. Youle, Sabine Kinloch-de Loes, Fiona C. Lampe, Sara Madge, et.al. Factors Influencing Increases in

- CD4 Cell Counts of HIV-Positive Persons Receiving Long-Term Highly Active Antiretroviral Therapy. *The Journal of Infectious Disease* 2004; 190:1860-8.
41. WHO. HIV/AIDS programme. Consolidated Guidelines on the use of Antiretroviral Drugs for Treating and Preventing HIV Infection June 2013.
 42. Nasronudin. Profilaksis dan Penatalaksanaan HIV/AIDS Penderita Dewasa. In: HIV dan AIDS Pendekatan Biologi Molekuler, Klinis, dan Sosial. Editor: Barakbah J, Soewandojo E, Suharto, Hadi U, Astuti WD. Surabaya: Airlangga University Press; 2007. p. 250; 253-4.
 43. DEPKES. Pedoman Tata Laksana Klinis Infeksi HIV dan Terapi Antiretroviral pada Orang Dewasa dan Remaja. Kementerian Kesehatan RI: Jakarta, 2012
 44. AIDS Information, Education, Action, and Awareness [internet]. c2013 [cited 2013 December 10]. Available from : <http://www.aids.org/topics/aids-factsheets/aids-background-information/what-is-aids/hiv-testing/cd4-t-cell-tests/>.
 45. HIV and AIDS Health Center. HIV, AIDS, and the CD4 Count [internet]. c2005-2013 [cited 2013 December 10]. Available from : <http://www.webmd.com/hiv-aids/cd4-count-what-does-it-mean>.
 46. Tuan Le, M.D., Dr.P.H., Edwina J. Wright, M.D., Davey M. Smith, M.D., Weijing He, M.D., Gabriel Catano, M.D., Jason F, et.al. Enhanced CD4+ T-Cell Recovery with Earlier HIV-1 Antiretroviral Therapy. *The New England Journal of Medicine*. 2013; 368: 218-30.
 47. Viard JP, Amanda Mocroft, Antonio Chiesi, Ole Kirk, Birgit Roge, George Panos, et.al. Influence of Age on CD4 Cell Recovery in Human Immunodeficiency Virus–Infected Patients Receiving Highly Active Antiretroviral Therapy Evidence from the EuroSIDA Study. *The Journal of Infectious Disease*. 2001; 183: 1290-4.
 48. Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm R, dkk. Lymphocyte subsets in healthy children from birth through



- 18 years of age: The Pediatric AIDS Clinical Trials Group P1009 Study. *J Allergy Clin Immunol* 2003;112:973–80.
49. Ruel TD, Brian C. Zanoni, Isaac Ssewanyana, Huyen Cao, Diane V. Havlir, Moses Kanya, et.al. Sex Differences in HIV RNA Level and CD4 Cell Percentage During Childhood. *Clinical Infectious Diseases* 2011;53(6):592–9.
50. Foca M, Moye J, Chu C, Matthews Y, Rich K, Handelsman E, dkk. Gender differences in lymphocyte populations, plasma HIV RNA levels, and disease progression in a cohort of children born to women infected with HIV. *Pediatrics* 2006;118:146–56.
51. Astari L, Sawitri, Safitri YE, Hinda D. *Viral load* pada infeksi HIV. *Berkala Ilmu Kesehatan Kulit dan Kelamin*. 2009; 21(1):31-8.
52. HIV/AIDS. What is viral load [internet]. Washington DC; c2009 [cited 2014 February 7]. Available from: <http://aids.gov/hiv-aids-basics/just-diagnosed-with-hiv-aids/understand-your-test-results/viral-load/>.
53. JW Mellors, A Munoz, JV Giorgi, JB Margolick, CJ Tassoni, P Gupta et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. *Ann Intern Med*. 1997; 126(12):946-54.
54. R Baker. HIV viral load supercedes CD4 count as best marker for predicting risk of AIDS and death. *BETA*.1996; 9-11. (Abstract).
55. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan Departemen Kesehatan RI. Pedoman Tatalaksana Infeksi HIV dan Terapi Antiretroviral Pada Anak Di Indonesia. Jakarta: Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan Departemen Kesehatan RI; 2010. p16,62-63.
56. Fergusson P, Tomkins A, Kerac M. Improving survival of children with severe acute malnutrition in HIV-prevalent settings. *Intern Health* 2009;1:10–6.
57. Nasronudin. Stres Oksidatif, Antioksidan, dan Pengaruhnya terhadap Progresivitas Infeksi HIV. In: *HIV dan AIDS Pendekatan Biologi*

- Molekuler, Klinis, dan Sosial. Editor: Barakbah J, Soewandojo E, Suharto, Hadi U, Astuti WD. Surabaya: Airlangga University Press; 2007. p. 96-97.
58. Wainberg MA, Zaharatos GJ, Brenner BG. Development of Antiretroviral Drug Resistance. *N Engl J Med*. 2011; 365:637-46.
59. Volberding PA, Warner CG, Joep MAL, Joel EG, Nelson S. HIV/AIDS medicine : Medical management of AIDS 2013. Elsevier. p.147.
60. Horn T. HIV drug resistance and resistance testing. 2001.
61. Kotler DP, Donald M Thea, Moonseong Heo, David B Allison, Ellen S Engelson, Jack Wang, Relative influences of sex, race, environment, and HIV infection on body composition in adults.
62. Suttman U. Incidence and Prognostic Value of Malnutrition and Wasting in HIV-infected Outpatients. *Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology*. 1994; 8: 246-99.
63. Mahlungulu S, Grobler LA, Visser ME, Volmink J. Nutritional interventions for reducing morbidity and mortality in people with HIV. *NCBI. Rev*. 2007 Jul 18;(3):CD004536. (Abstract).
64. Ndeezi G, Tylleskär T, Ndugwa CM, Tumwine JK. Effect of multiple micronutrient supplementation on survival of HIV-infected children in Uganda. *J Int AIDS Soc* 2010; 13:18. doi: 10.1186/1758-2652-13-18.
65. Johannessen A, Naman E, Ngowi BJ, et al. Predictors of mortality in HIVinfected patients starting antiretroviral therapy in a rural hospital in Tanzania. *BMC Infect Dis*. 2008;8:52.
66. Mangili A, D. H. Murman, A. M. Zampini, and C. A. Wanke1. Nutrition and HIV Infection: Review of Weight Loss and Wasting in the Era of Highly Active Antiretroviral Therapy from the Nutrition for Healthy Living Cohort. *Clinical Infectious Diseases* 2006; 42:836–42.
67. Arpadi MS. Growth failure in HIV-infected children. South Africa. 2005.
68. Direktorat Jenderal Bina Gizi dan Kesehatan Ibu dan Anak Kementerian Kesehatan RI. Standar Antropometri Penilaian Status Gizi Anak. Jakarta (Indonesia); 2011.

69. Banerjee T, Pensi T, Banerjee D, Grover G. Impact of HAART on survival, weight gain and resting energy expenditure in HIV-1-infected children in India. NCBI. 2010; 30(1):27-37. doi: 10.1179/146532810X12637745451915. (Abstract)
70. Supportive care issues for children with HIV infection. Available from: <http://www.hivguidelines.org/GuidelineDocuments/p-suppcare.pdf>.
71. Koethe JR, Lukusa A, Giganti MJ, Chi BH, Nyirenda CK, Limbada MI, et.al. Association between weight gain and clinical outcomes among malnourished adults initiating antiretroviral therapy in Lusaka, Zambia. *J Acquir Immune Defic Syndr*. 2010 Apr 1;53(4):507-13.
72. Mwiru RS, Spiegelman D, Duggan C, Seage GR 3rd, Semu H, Chalamilla G, dkk. Growth among HIV-infected Children Receiving Antiretroviral Therapy in Dar es Salaam, Tanzania. *J Trop Pediatr*. 2014; 60(3):179-88. (Abstract)
73. Reda AA, Biadgilign S, Deribew A, Gebre B, Deribe K. Predictors of Change in CD4 Lymphocyte Count and Weight among HIV Infected Patients on Anti-Retroviral Treatment in Ethiopia: A Retrospective Longitudinal Study. 2013. *PLoS ONE* 8(4): e58595. doi:10.1371/journal.pone.0058595.
74. Tristina, nina. Analisis Generalized Estimating Equations (GEE) untuk menilai perubahan limfosit-CD4 pada Injecting Drug Users (IDU) dan non-IDU Penderita HIV/AIDS di Klinik Teratai RSUP Dr. Hasan Sadikin Bandung. 2010.

LAMPIRAN

Lampiran 1. Ethical clearance

	<p>KOMISI ETIK PENELITIAN KESEHATAN (KEPK) FAKULTAS KEDOKTERAN UNIVERSITAS DIPONEGORO DAN RSUP dr KARIADI SEMARANG Sekretariat : Kantor Dekanat FK Undip Lt.3 Jl. Dr. Soetomo 18. Semarang 50231 Telp/Fax. 024-8318350</p>	
---	--	---

ETHICAL CLEARANCE
No. 151/EC/FK-RSDK/2014

Komisi Etik Penelitian Kesehatan Fakultas Kedokteran Universitas Diponegoro/ RSUP Dr. Kariadi Semarang, setelah membaca dan menelaah Usulan Penelitian dengan judul :

**FAKTOR DETERMINAN PENINGKATAN JUMLAH CD4 DAN BERAT BADAN ANAK HIV/AIDS SETELAH ENAM BULAN TERAPI ANTIRETROVIRAL:
Penelitian Cohort Retrospective terhadap usia, Jenis Kelamin, Stadium klinis, Lama terapi antiretroviral**

Peneliti Utama : Arya Ady Nugroho

Pembimbing : 1. dr. MMDEAH Hapsari, Sp.A(K)
2. dr. Helmia Farida, Sp.A, M.Kes

Penelitian : Di laksanakan di Instalasi Rekam Medik RSUP Dr. Kariadi Semarang.


Setuju untuk dilaksanakan, dengan memperhatikan prinsip-prinsip yang dinyatakan dalam Deklarasi Helsinki 1975, yang diamended di Seoul 2008 dan Pedoman Nasional Etik Penelitian Kesehatan (PNEPK) Departemen Kesehatan RI 2011

Peneliti harus melampirkan 2 kopi lembar Informed consent yang telah disetujui dan ditandatangani oleh peserta penelitian pada laporan penelitian.
Peneliti diwajibkan menyerahkan :


- Laporan kemajuan penelitian (clinical Trial)
- Laporan kejadian efek samping jika ada
- Laporan ke KEPK jika penelitian sudah selesai & dilampiri Abstrak Penelitian.

Semarang, 10 APR 2014

Komisi Etik Penelitian Kesehatan
Fakultas Kedokteran Undip-RSUP Dr. Kariadi
Sekretaris,


Dr.dr.Selama Budijitno, M.Si.Med,Sp.B,Sp.B(K),Onk,FICS
NIP. 197108072 008121 001

Lampiran 2. Surat perijinan penelitian



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS DIPONEGORO
FAKULTAS KEDOKTERAN
 Jl. Prof. H. Soedarto, SH – Tembalang – Semarang
 Telepon 024-76928010, Fax. 024-76928011, Email : dean_fmdu@undip.ac.id

Nomor : 1560 /UN7.3.4/D1/PP/2014 21 MAR 2014
 Lampiran : 1 bendel
 Perihal : Permohonan ijin penelitian dan pengambilan data rekam medik

Yth. Direktur Utama
 RSUP Dr. Kariadi
 Semarang

Dengan hormat,

Bersama ini kami hadapkan mahasiswa Fakultas Kedokteran Universitas Diponegoro Semarang :


Nama : Arya Ady Nugroho
 NIM : 22010110110095
 Semester : VIII (delapan)

Mohon diijinkan melakukan penelitian dan meminjam data rekam medik di Instalasi Rekam Medik RSUP Dr. Kariadi Semarang, dalam rangka penyusunan Karya Tulis Ilmiah mahasiswa. Terlampir proposal mahasiswa yang bersangkutan.

Judul/ Topik : Faktor Determinan Peningkatan Jumlah CD4 dan Berat Badan Anak HIV/AIDS Setelah Enam Bulan Terapi Antiretroviral

Pembimbing : dr. MMDEAH Hapsari, Sp.A(K)/ dr. Helmia Farida, Sp.A, M.Kes


Atas perhatian dan kerjasamanya diucapkan terima kasih.

a.n Dekan
 Pembantu Dekan I,

 dr. Herman Kristanto, MS, Sp. OG(K)
 NIP. 196305051989031003 7


Tembusan :

1. Dekan (sebagai laporan)
2. Ketua Tim Karya Tulis Ilmiah
3. Kepala Bagian Diklit RSUP Dr. Kariadi Semarang
4. Kepala Instalasi Rekam Medik RSUP Dr. Kariadi Semarang
5. Pembimbing
6. Mahasiswa Yang Bersangkutan

Lampiran 3. Surat peminjaman rekam medik



KEMENTERIAN KESEHATAN RI
DIREKTORAT JENDERAL BINA UPAYA KESEHATAN
RUMAH SAKIT UMUM PUSAT DOKTER KARIADI
 Jalan Dr. Sutomo No. 16 Semarang, PO BOX 1104
 Telepon : (024) 8413993, 8413476, 8413764 Fax : (024) 8318617
 Website : <http://www.rskariadi.com> email : rsdk@indosat.net.id ; rsdk@rskariadi.com



RSUP Dr. KARIADI
 Sehat Menjamin Sehat

Nomor : DL.00.02 / I.II / 1278 / 2014
 Lamp. : -
 Perihal : *Penelitian* 20 MAY 2014

Yth. Dekan Fakultas Kedokteran
 Universitas Diponegoro
 Jl. Prof. H. Soedarto, SH. Tembalang
 di - SEMARANG

Menindak lanjuti surat Saudara No.1560/UN7.3.4/D1/PP/2014 tanggal 21 Maret 2014 perihal Permohonan ijin penelitian dan pengambilan data rekam medis, dengan ini kami sampaikan bahwa :


Nama peneliti : Arya Ady Nugroho
 Judul penelitian : Faktor Determinan Peningkatan Jumlah CD4 dan Berat Badan Anak HIV/AIDS Setelah Enam Bulan Terapi Antiretroviral (Penelitian Cohort Retrospective Terhadap Usia, Jenis Kelamin, Stadium Klinis, Lama Terapi Antiretroviral)
 Pembimbing I : dr. MMDEAH Hapsari, Sp.A(K)
 II : dr. Helmia Farida, Sp.A, M.Kes
 DPJP : -

pada prinsipnya diizinkan untuk melaksanakan Penelitian di Instalasi Rekam Medis RSUP Dr. Kariadi dengan ketentuan :

- ✚ Waktu pelaksanaan penelitian dapat dilakukan sewaktu hari kerja selama ±2 bulan, dengan jumlah sampel yang dibutuhkan adalah ±80 CM
- ✚ Tidak mengganggu pelayanan.
- ✚ Pihak Institusi dan mahasiswa dapat mentaati peraturan serta tata-tertib yang berlaku di RSUP Dr. Kariadi.
- ✚ Memberikan laporan hasil penelitian kepada RSUP Dr. Kariadi dan Bagian/Instalasi tempat penelitian dilaksanakan.

Atas perhatian dan kerjasama Saudara diucapkan terima kasih.

An. Direktur Utama
 Direktur SDM dan Pendidikan



Dr. Agus Suryanto, Sp.PD-KP, MARS
 NIP. 19610818 198812 1 001

Tembusan Yth :

1. Direktur Utama RSUP Dr. Kariadi (*sebagai laporan*)
2. Ka.Inst. Rekam Medis
3. Ka.Inst. Diklat
- √ 4. Yang bersangkutan

Lampiran 4. Hasil analisis SPSS

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
usia (tahun)	,143	33	,084	,854	33	,000
BB sebelum (kg)	,191	33	,004	,912	33	,011
BB setelah (kg)	,155	33	,042	,925	33	,026

a. Lilliefors Significance Correction

Descriptives

		Statistic	Std. Error	
usia (tahun)	Mean	4,0480	,58044	
	95% Confidence Interval for Mean	Lower Bound	2,8657	
		Upper Bound	5,2303	
	5% Trimmed Mean	3,8032		
	Median	3,2500		
	Variance	11,118		
	Std. Deviation	3,33438		
	Minimum	,42		
	Maximum	12,25		
	Range	11,83		
	Interquartile Range	4,04		
	Skewness	1,226	,409	
	Kurtosis	,735	,798	
	BB sebelum (kg)	Mean	10,9303	,77720
95% Confidence Interval for Mean		Lower Bound	9,3472	
		Upper Bound	12,5134	
5% Trimmed Mean		10,5993		
Median		10,0000		
Variance		19,933		
Std. Deviation		4,46469		
Minimum		5,00		
Maximum		24,00		
Range		19,00		
Interquartile Range		5,30		

	Skewness	1,113	,409
	Kurtosis	1,398	,798
BB setelah (kg)	Mean	12,8394	,93554
	95% Confidence Interval for Mean	Lower Bound Upper Bound	10,9338 14,7450
	5% Trimmed Mean	12,5539	
	Median	12,5000	
	Variance	28,882	
	Std. Deviation	5,37424	
	Minimum	1,40	
	Maximum	28,00	
	Range	26,60	
	Interquartile Range	6,00	
	Skewness	,946	,409
	Kurtosis	2,172	,798

Frequencies

kategori usia 1 tahun

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid usia >=1 tahun	27	81,8	81,8	81,8
usia <1 tahun	6	18,2	18,2	100,0
Total	33	100,0	100,0	

Jenis Kelamin

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Laki-laki	20	60,6	60,6	60,6
Perempuan	13	39,4	39,4	100,0
Total	33	100,0	100,0	

Stadium klinis pasien (WHO)

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid stadium klinis 1	4	12,1	12,1	12,1
stadium klinis 2	6	18,2	18,2	30,3
stadium klinis 3	16	48,5	48,5	78,8
stadium klinis 4	7	21,2	21,2	100,0
Total	33	100,0	100,0	

Status gizi sebelum terapi ARV

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Gizi Normal +2 s.d. > -2	10	30,3	34,5	34,5
Gizi kurang < -2 s.d. -3	2	6,1	6,9	41,4
Gizi buruk < -3	17	51,5	58,6	100,0
Total	29	87,9	100,0	
Missing System	4	12,1		
Total	33	100,0		

Status gizi setelah terapi

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Gizi Normal +2 s.d. > -2	16	48,5	55,2	55,2
Gizi kurang < -2 s.d. -3	7	21,2	24,1	79,3
Gizi buruk < -3	6	18,2	20,7	100,0
Total	29	87,9	100,0	
Missing System	4	12,1		
Total	33	100,0		

Riwayat Ibu HIV positif

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid ya	33	100,0	100,0	100,0

domisili

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid semarang	11	33,3	33,3	33,3
luar semarang	22	66,7	66,7	100,0
Total	33	100,0	100,0	

NPar Tests

Wilcoxon Signed Ranks Test

		N	Mean Rank	Sum of Ranks
WAZ setelah terapi - WAZ sebelum terapi	Negative Ranks	14 ^a	7,68	107,50
	Positive Ranks	1 ^b	12,50	12,50
	Ties	14 ^c		
	Total	29		

a. WAZ setelah terapi < WAZ sebelum terapi

b. WAZ setelah terapi > WAZ sebelum terapi

c. WAZ setelah terapi = WAZ sebelum terapi

Test Statistics^a

	WAZ setelah terapi - WAZ sebelum terapi
Z	-2,786 ^b
Asymp. Sig. (2-tailed)	,005

a. Wilcoxon Signed Ranks Test

b. Based on positive ranks.

Crosstab

kategori usia 1 tahun * Berat badan evaluasi

			Berat badan evaluasi		Total
			Sesuai target	Tidak sesuai target	
kategori usia 1 tahun	usia >=1 tahun	Count	24	3	27
		% within kategori usia 1 tahun	88,9%	11,1%	100,0%
	usia <1 tahun	Count	5	1	6
		% within kategori usia 1 tahun	83,3%	16,7%	100,0%

Total	Count	29	4	33
	% within kategori usia 1 tahun	87,9%	12,1%	100,0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	,142 ^a	1	,706		
Continuity Correction ^b	,000	1	1,000		
Likelihood Ratio	,132	1	,716		
Fisher's Exact Test				1,000	,571
Linear-by-Linear Association	,138	1	,710		
N of Valid Cases	33				

a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is ,73.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for kategori usia 1 tahun (usia >=1 tahun / usia <1 tahun)	1,600	,137	18,723
For cohort Berat badan evaluasi = Sesuai target	1,067	,728	1,563
For cohort Berat badan evaluasi = Tidak sesuai target	,667	,083	5,353
N of Valid Cases	33		

Jenis Kelamin * Berat badan evaluasi

			Berat badan evaluasi		Total
			Sesuai target	Tidak sesuai target	
Jenis Kelamin	Laki-laki	Count	17	3	20
		% within Jenis Kelamin	85,0%	15,0%	100,0%
	Perempuan	Count	12	1	13
		% within Jenis Kelamin	92,3%	7,7%	100,0%
Total		Count	29	4	33
		% within Jenis Kelamin	87,9%	12,1%	100,0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	,395 ^a	1	,530		
Continuity Correction ^b	,007	1	,934		
Likelihood Ratio	,417	1	,519		
Fisher's Exact Test				1,000	,481
Linear-by-Linear Association	,383	1	,536		
N of Valid Cases	33				

a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is 1,58.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Jenis Kelamin (Laki-laki / Perempuan)	,472	,044	5,106
For cohort Berat badan evaluasi = Sesuai target	,921	,723	1,173
For cohort Berat badan evaluasi = Tidak sesuai target	1,950	,227	16,787
N of Valid Cases	33		

Stadium klinis WHO*Berat badan evaluasi

			Berat badan evaluasi		Total
			Sesuai target	Tidak sesuai target	
Stadium Klinis WHO	Stadium	Count	8	2	10
	Klinis 1 dan 2	% within Stadium Klinis WHO	80,0%	20,0%	100,0%
	Stadium	Count	21	2	23
	Klinis 3 dan 4	% within Stadium Klinis WHO	91,3%	8,7%	100,0%
Total		Count	29	4	33
		% within Stadium Klinis WHO	87,9%	12,1%	100,0%

\

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	,836 ^a	1	,361		
Continuity Correction ^b	,112	1	,738		
Likelihood Ratio	,778	1	,378		
Fisher's Exact Test				,567	,351
Linear-by-Linear Association	,811	1	,368		
N of Valid Cases	33				

a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is 1,21.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Stadium Klinis WHO (Stadium Klinis 1 dan 2 / Stadium Klinis 3 dan 4)	,381	,046	3,181
For cohort Berat badan evaluasi = Sesuai target	,876	,627	1,224
For cohort Berat badan evaluasi = Tidak sesuai target	2,300	,375	14,109
N of Valid Cases	33		

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
usia (tahun)	,243	17	,009	,785	17	,001
CD4 sebelum terapi ARV	,229	17	,019	,801	17	,002
CD4 setelah terapi	,189	17	,110	,866	17	,019

a. Lilliefors Significance Correction

Descriptives

		Statistic	Std. Error	
usia (tahun)	Mean	3,6716	,83564	
	95% Confidence Interval for Mean	Lower Bound	1,9001	
		Upper Bound	5,4431	
	5% Trimmed Mean	3,3573		
	Median	2,4167		
	Variance	11,871		
	Std. Deviation	3,44544		
	Minimum	,75		
	Maximum	12,25		
	Range	11,50		
	Interquartile Range	3,33		
	Skewness	1,575	,550	
	Kurtosis	1,626	1,063	
	CD4 sebelum terapi ARV	Mean	229,47	57,381
95% Confidence Interval for Mean		Lower Bound	107,83	
		Upper Bound	351,11	
5% Trimmed Mean		211,91		
Median		123,00		
Variance		55973,640		
Std. Deviation		236,587		
Minimum		8		
Maximum		767		
Range		759		
Interquartile Range		271		
Skewness		1,427	,550	
Kurtosis		1,025	1,063	
CD4 setelah terapi		Mean	600,2353	112,82474
	95% Confidence Interval for Mean	Lower Bound	361,0575	
		Upper Bound	839,4131	
	5% Trimmed Mean	570,7614		
	Median	481,0000		
	Variance	216400,191		
	Std. Deviation	465,18834		
	Minimum	81,00		

Maximum	1650,00	
Range	1569,00	
Interquartile Range	576,50	
Skewness	1,239	,550
Kurtosis	1,138	1,063

Frequency Table

kategori usia 1 tahun

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	usia >=1 tahun	14	42,4	82,4	82,4
	usia <1 tahun	3	9,1	17,6	100,0
	Total	17	51,5	100,0	
Missing	System	16	48,5		
Total		33	100,0		

Jenis Kelamin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-laki	12	36,4	70,6	70,6
	Perempuan	5	15,2	29,4	100,0
	Total	17	51,5	100,0	
Missing	System	16	48,5		
Total		33	100,0		

Stadium klinis pasien (WHO)

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	stadium klinis 1	2	6,1	11,8	11,8
	stadium klinis 2	2	6,1	11,8	23,5
	stadium klinis 3	10	30,3	58,8	82,4
	stadium klinis 4	3	9,1	17,6	100,0
	Total	17	51,5	100,0	
Missing	System	16	48,5		
Total		33	100,0		

Status Imunologi sebelum terapi

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	imunosupresi sedang	3	9,1	17,6	17,6
	Imunosupresi berat	14	42,4	82,4	100,0
	Total	17	51,5	100,0	
Missing	System	16	48,5		
Total		33	100,0		

Status Imunologi setelah terapi

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak ada imunosupresi	2	6,1	11,8	11,8
	imunosupresi sedang	6	18,2	35,3	47,1
	Imunosupresi berat	9	27,3	52,9	100,0
	Total	17	51,5	100,0	
Missing	System	16	48,5		
Total		33	100,0		

Riwayat Ibu HIV positif

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	17	51,5	100,0	100,0
Missing	System	16	48,5		
Total		33	100,0		

domisili

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	semarang	11	33,3	33,3	33,3
	luar semarang	22	66,7	66,7	100,0
	Total	33	100,0	100,0	

NPar Tests

Wilcoxon Signed Ranks Test

		N	Mean Rank	Sum of Ranks
Status Imunologi setelah terapi - Status Imunologi sebelum terapi	Negative Ranks	7 ^a	4,00	28,00
	Positive Ranks	0 ^b	,00	,00
	Ties	10 ^c		
	Total	17		

a. Status Imunologi setelah terapi < Status Imunologi sebelum terapi

b. Status Imunologi setelah terapi > Status Imunologi sebelum terapi

c. Status Imunologi setelah terapi = Status Imunologi sebelum terapi

Test Statistics^a

	Status Imunologi setelah terapi - Status Imunologi sebelum terapi
Z	-2,646 ^b
Asymp. Sig. (2-tailed)	,008

a. Wilcoxon Signed Ranks Test

b. Based on positive ranks.

Crosstab

kategori usia 1 tahun * Jumlah CD4 evaluasi

			Jumlah CD4 evaluasi		Total
			>=8sel/mm3/bulan	<8 sel/mm3/bulan	
kategori usia 1 tahun	usia >=1 tahun	Count	12	2	14
		% within kategori usia 1 tahun	85,7%	14,3%	100,0%
	usia <1 tahun	Count	2	1	3
		% within kategori usia 1 tahun	66,7%	33,3%	100,0%
Total		Count	14	3	17
		% within kategori usia 1 tahun	82,4%	17,6%	100,0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	,617 ^a	1	,432		
Continuity Correction ^b	,000	1	1,000		
Likelihood Ratio	,542	1	,462		
Fisher's Exact Test				,465	,465
Linear-by-Linear Association	,580	1	,446		
N of Valid Cases	17				

a. 3 cells (75,0%) have expected count less than 5. The minimum expected count is ,53.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for kategori usia 1 tahun (usia >=1 tahun / usia <1 tahun)	3,000	,177	50,784
For cohort Jumlah CD4 evaluasi = >=8sel/mm3/bulan	1,286	,562	2,943
For cohort Jumlah CD4 evaluasi = <8 sel/mm3/bulan	,429	,055	3,333
N of Valid Cases	17		

Jenis Kelamin * Jumlah CD4 evaluasi

			Jumlah CD4 evaluasi		Total
			>=8sel/mm3/bulan	<8 sel/mm3/bulan	
Jenis Kelamin	Laki-laki	Count	10	2	12
		% within Jenis Kelamin	83,3%	16,7%	100,0%
	Perempuan	Count	4	1	5
		% within Jenis Kelamin	80,0%	20,0%	100,0%
Total		Count	14	3	17
		% within Jenis Kelamin	82,4%	17,6%	100,0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	,027 ^a	1	,870		
Continuity Correction ^b	,000	1	1,000		
Likelihood Ratio	,026	1	,871		
Fisher's Exact Test				1,000	,676
Linear-by-Linear Association	,025	1	,873		
N of Valid Cases	17				

a. 3 cells (75,0%) have expected count less than 5. The minimum expected count is ,88.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Jenis Kelamin (Laki-laki / Perempuan)	1,250	,087	17,975
For cohort Jumlah CD4 evaluasi = >=8sel/mm3/bulan	1,042	,628	1,728
For cohort Jumlah CD4 evaluasi = <8 sel/mm3/bulan	,833	,096	7,240
N of Valid Cases	17		

Stadium Klinis WHO * Jumlah CD4 evaluasi

			Jumlah CD4 evaluasi		Total
			>=8sel/mm3/bulan n	<8 sel/mm3/bulan	
Stadium Klinis WHO	Stadium Klinis WHO dan 2	Count	3	1	4
		% within Stadium Klinis WHO dan 2	75,0%	25,0%	100,0%
	Stadium Klinis WHO dan 4	Count	11	2	13
		% within Stadium Klinis WHO dan 4	84,6%	15,4%	100,0%
Total		Count	14	3	17
		% within Stadium Klinis WHO	82,4%	17,6%	100,0%

Chi-Square Tests


	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	,195 ^a	1	,659		
Continuity Correction ^b	,000	1	1,000		
Likelihood Ratio	,183	1	,669		
Fisher's Exact Test				1,000	,579
Linear-by-Linear Association	,183	1	,669		
N of Valid Cases	17				

a. 3 cells (75,0%) have expected count less than 5. The minimum expected count is ,71.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Stadium Klinis WHO (Stadium Klinis 1 dan 2 / Stadium Klinis 3 dan 4)	,545	,036	8,270
For cohort Jumlah CD4 evaluasi = >=8sel/mm3/bulan	,886	,481	1,634
For cohort Jumlah CD4 evaluasi = <8 sel/mm3/bulan	1,625	,195	13,576
N of Valid Cases	17		

Lampiran 5. Dokumentasi penelitian**Gambar 10. Pengambilan data rekam medik**

Lampiran 6. Biodata mahasiswa**Identitas**

Nama : Arya Ady Nugroho
NIM : 22010110110095
Tempat / tanggal lahir: Kendal / 17 Mei 1992
Jenis Kelamin : Laki-laki
Alamat : Ds. Banyuurip RT 1 RW 3 Kec. Ngampel Kab. Kendal
Nomor HP : 085641948794
e-mail : aryaadyn@yahoo.com

Riwayat Pendidikan Formal

- | | | | |
|--------|---|-------------|--------|
| 1. SD | : SD Negeri 1 Banyuurip | Lulus tahun | : 2004 |
| 2. SMP | : SMP Negeri 2 Kendal | Lulus tahun | : 2007 |
| 3. SMA | : SMA Negeri 1 Kendal | Lulus tahun | : 2010 |
| 4. S1 | : Pendidikan Dokter Fakultas Kedokteran
Universitas Diponegoro | Masuk tahun | : 2010 |